Asciminib Shows Clinical Activity for Pretreated CML in Phase 1 Trial
Asciminib appeared to have clinical activity in a population of heavily pretreated patients with chronic myeloid leukemia, including those with a T315I mutation.
Chronic Myeloid Leukemia News
CHRONIC MYELOID LEUKEMIA ADVISOR
Chronic Myeloid Leukemia News
Adherence to Other Oral Medications Declines Following Introduction of Oral Oncolytics
This study assessed levels of adherence to antihypertensive, lipid-lowering, and antidiabetic therapy in patients initiating oral oncology therapy for a hematologic cancer.
Follow-Up Results of Low-Dose Dasatinib for Chronic-Phase Chronic Myeloid Leukemia
Patients received 50 mg dasatinib daily and demonstrated 2-year rates of overall and event-free survival of 100%.
Blast Count Prognostic for CML Presenting in Advanced Phase
Mortality risk significantly higher for patients with 20 to 29 percent versus less than 20 percent blasts.
Study Compares Quality of Life for Patients With Chronic Myeloid Leukemia Treated With Dasatinib vs Imatinib
Using validated assessment tools, researchers compared patients’ perceptions of HRQOL while undergoing treatment for CML with 1 of 2 TKIs.
Outcomes With Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Nilotinib was associated with high adherence to treatment and fairly high quality of life, and nearly all evaluated patients achieved a major molecular response.
Some Discrepancies Seen Between Real-Life and Guideline-Recommended Care of Chronic Myeloid Leukemia
An assessment of a population of patients with CML revealed that some are not receiving guideline-based treatment, including TKIs.
Flumatinib Shows Promise in Chronic-Phase Chronic Myeloid Leukemia
A significantly greater proportion of patients in the flumatinib group had a complete molecular response at 12 months compared with in the imatinib group.
Second-Generation TKIs in Advanced CML: 7-Year Survival Rates
In patients who have been newly diagnosed with AP-CML, the initiation of TKI2 therapies in the frontline setting provided excellent responses and survival rates.
Generic Imatinib Compared With Gleevec in CP-CML: Patient Outcomes Across 3 Countries
Although the study suggested the efficacy of the branded version was superior to its generic counterpart, more research may be necessary to tease out manufacturer differences.
Prototype Intervention Increased Adherence to TKIs in CML
A prototype intervention increased adherence to tyrosine kinase inhibitor therapy in some patients with chronic myeloid leukemia.
Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
A new method for rapid, ultrasensitive detection of BCR-ABL1 mRNA in chronic myeloid leukemia was described; the tool may have diagnostic utility.
New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro
The addition of AR-42 to imatinib yielded synergistic activity in chronic myeloid leukemia cells and also appeared to reverse therapeutic resistance.
Dasatinib in Chronic Myeloid Leukemia Linked to Higher Health Care Costs
Increased costs were found to be a result of more infections.
Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML
For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.
Second-Generation TKIs May Be Effective After First-Line Imatinib Failure in Pediatric CML
There is a paucity of data on the use of second-generation tyrosine kinase inhibitors among pediatric patients with chronic-phase chronic myeloid leukemia.
Time of Response to TKI Therapies May Influence Patient Outcomes in CML
Early optimal response to TKIs is associated with reductions in treatment failures, poor outcomes, progression of disease, and death.
2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML
For the single-treatment STAT2 phase 2 study, researchers enrolled 96 Japanese patients with chronic myeloid leukemia who had achieved a deep molecular response during the consolidation phase of treatment with nilotinib.
Recurrence-Free Survival May Be Sustainable After De-Escalation or Stoppage of TKI Therapy in CML
Disease recurrence remained low among patients with CML who reduced or discontinued TKI therapy after achieving major response.
Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML
Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.
Want to read more?
Please login or register first to view this content.
